S
Sentiljana Gumeni
Researcher at National and Kapodistrian University of Athens
Publications - 45
Citations - 1009
Sentiljana Gumeni is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 11, co-authored 34 publications receiving 384 citations.
Papers
More filters
Journal ArticleDOI
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
Evangelos Terpos,Ioannis P. Trougakos,Filia Apostolakou,Ioanna Charitaki,Aimilia D. Sklirou,Nefeli Mavrianou,Eleni-Dimitra Papanagnou,Christine-Ivy Liacos,Sentiljana Gumeni,Gianna Rentziou,Eleni Korompoki,Ioannis Papassotiriou,Meletios A. Dimopoulos +12 more
Journal ArticleDOI
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.
Cristina Bergamaschi,Evangelos Terpos,Margherita Rosati,Matthew Angel,Jenifer Bear,Dimitris Stellas,Sevasti Karaliota,Filia Apostolakou,Tina Bagratuni,Dimitris Patseas,Sentiljana Gumeni,Ioannis P. Trougakos,Meletios A. Dimopoulos,Barbara K. Felber,George N. Pavlakis +14 more
TL;DR: In this article, the 1st and 2nd doses of BNT162b2 mRNA (Pfizer/BioNtech) vaccine in antigen-naive and in previously coronavirus disease 2019 (COVID-19)-infected individuals (NCT04743388) were compared.
Journal ArticleDOI
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
Evangelos Terpos,Maria Gavriatopoulou,Ioannis Ntanasis-Stathopoulos,Alexandros Briasoulis,Sentiljana Gumeni,Panagiotis Malandrakis,Despina Fotiou,Eleni-Dimitra Papanagnou,Magdalini Migkou,Foteini Theodorakakou,Maria Roussou,Evangelos Eleutherakis-Papaiakovou,Nikolaos Kanellias,Ioannis P. Trougakos,Efstathios Kastritis,Meletios A. Dimopoulos +15 more
TL;DR: In this article, neutralizing antibodies against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22 and 50.
Journal ArticleDOI
Spastin binds to lipid droplets and affects lipid metabolism.
Chrisovalantis Papadopoulos,Genny Orso,Giuseppe Mancuso,Marija Herholz,Sentiljana Gumeni,Nimesha Tadepalle,Christian Jüngst,Anne Tzschichholz,Astrid Schauss,Stefan Höning,Aleksandra Trifunovic,Andrea Daga,Elena I. Rugarli +12 more
TL;DR: The data uncovers an evolutionarily conserved role of spastin as a positive regulator of LD metabolism and open up the possibility that dysfunction of LDs in axons may contribute to the pathogenesis of HSP.
Journal ArticleDOI
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Ioannis P. Trougakos,Evangelos Terpos,Christina Zirou,Aimilia D. Sklirou,Filia Apostolakou,Sentiljana Gumeni,Ioanna Charitaki,Eleni-Dimitra Papanagnou,Tina Bagratuni,Christine-Ivy Liacos,Andreas Scorilas,Eleni Korompoki,Ioannis Papassotiriou,Efstathios Kastritis,Meletios A. Dimopoulos +14 more
TL;DR: In this article, the authors found that one (boosting) dose of the BNT162b2 vaccine triggers robust immune responses in COVID-19 convalescent healthy recipients, while naive recipients require both priming and boosting shots to acquire high antibody titers.